Literature DB >> 28946803

Anti-biofilm activity of a sophorolipid-amphotericin B niosomal formulation against Candida albicans.

Farazul Haque1, Mohammad Sajid2, Swaranjit Singh Cameotra2, Mani Shankar Battacharyya1.   

Abstract

Sophorolipids (SLs) have gained interest in the pharmaceutical industries due to their anti-microbial, anti-adhesive and anti-biofilm properties. In the present study, the production of SL was increased by using low-cost media components. The potential of a SL-based niosomal formulation of amphotericin B (AmB) was determined against biofilm of the opportunistic fungal pathogen Candida albicans. In-house prepared SL-AmB niosomes were characterized by different microscopic techniques. The mean entrapment efficiency of AmB within SL-AmB niosome was 63.20% ± 3.86. The cytotoxicity of SL-AmB on mature C. albicans biofilm was compared with an expensive, marketed drug, viz. phosome (a liposomal formulation of AmB). Fewer hyphae were observed in C. albicans biofilm treated with SL-AmB niosome whereas more budding cells were found in phosome treated biofilm. The present study has established the affordable production of SL and the suitability of this approach for delivery of poorly soluble drugs such as AmB against candidiasis infections.

Entities:  

Keywords:  Fermenter; amphotericin B; biofilm; biosurfactant; niosome; toxicity

Mesh:

Substances:

Year:  2017        PMID: 28946803     DOI: 10.1080/08927014.2017.1363191

Source DB:  PubMed          Journal:  Biofouling        ISSN: 0892-7014            Impact factor:   3.209


  9 in total

Review 1.  Biosurfactants: Secondary Metabolites Involved in the Process of Bioremediation and Biofilm Removal.

Authors:  Sushruta Bhadra; Dixita Chettri; Anil Kumar Verma
Journal:  Appl Biochem Biotechnol       Date:  2022-05-17       Impact factor: 2.926

2.  Amphotericin B and Curcumin Co-Loaded Porous Microparticles as a Sustained Release System against Candida albicans.

Authors:  Baiji Xue; Yanhua Yu; Guoqiang Peng; Mengmeng Sun; Peng Lv; Xuefeng Li
Journal:  Molecules       Date:  2022-05-11       Impact factor: 4.927

Review 3.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

Review 4.  Contributions of Glycolipid Biosurfactants and Glycolipid-Modified Materials to Antimicrobial Strategy: A Review.

Authors:  Qin Shu; Hanghang Lou; Tianyu Wei; Xiayu Liu; Qihe Chen
Journal:  Pharmaceutics       Date:  2021-02-06       Impact factor: 6.321

5.  Sophorolipid exhibits antifungal activity by ROS mediated endoplasmic reticulum stress and mitochondrial dysfunction pathways in Candida albicans.

Authors:  Farazul Haque; Nitish Kumar Verma; Mohammad Alfatah; Swati Bijlani; Mani Shankar Bhattacharyya
Journal:  RSC Adv       Date:  2019-12-16       Impact factor: 4.036

6.  Production of new antimicrobial palm oil-derived sophorolipids by the yeast Starmerella riodocensis sp. nov. against Candida albicans hyphal and biofilm formation.

Authors:  Achmad Rifky Alfian; Kwanrutai Watchaputi; Chayaphathra Sooklim; Nitnipa Soontorngun
Journal:  Microb Cell Fact       Date:  2022-08-17       Impact factor: 6.352

7.  Fungal Infected Adipose Stem Cells: The Effects of Novel Lipo-Niosome Nanoparticles Loaded with Amphotericin B and Thymus Essential Oil.

Authors:  Fardin Rahimi; Ghasem Amoabediny; Hossein Sabahi; Behrouz Zandieh-Doulabi
Journal:  Cell J       Date:  2022-07-27       Impact factor: 3.128

Review 8.  Sophorolipids-Bio-Based Antimicrobial Formulating Agents for Applications in Food and Health.

Authors:  Wei Yan Cho; Jeck Fei Ng; Wei Hsum Yap; Bey Hing Goh
Journal:  Molecules       Date:  2022-08-29       Impact factor: 4.927

9.  Microscopic Investigation of the Combined Use of Antibiotics and Biosurfactants on Methicillin Resistant Staphylococcus aureus.

Authors:  Abulaziz Juma; Patrick Lemoine; Alistair B J Simpson; Jason Murray; Barry M G O'Hagan; Patrick J Naughton; James G Dooley; Ibrahim M Banat
Journal:  Front Microbiol       Date:  2020-07-07       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.